Indeed, the proteasome inhibitor Bortezomib, a compound commonly used in the setting of multiple myeloma patients, impairs the physiological defensive response to iron overload that consists in CD71 degradation and ferritin increase, thus maximizing the toxicity of supplemented iron and leading to ferroptosis-mediated cell death [14, 59–61]. Here, TFRC is linked to plasma cell myeloma.